Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have developed a swallowable nanoscale delivery platform designed to transport therapeutic enzymes through the stomach's acidic environment and activate a cancer-killing reaction at tumor sites. Early preclinical findings suggest that the approach may offer a new strategy for treating gastric cancer more precisely while reducing damage to healthy tissue.